Wednesday, February 10, 2010, 10:40AM AEST - The Australian Stockmarket closes in 5 hours and 25 minutes.
To create a watchlist or portfolio of shares, Register

Alnylam Pharmaceuticals, Inc. (ALNY)

8:00AM AEST: 16.93 USD  Up 0.02 (0.12%)  
 MORE ON ALNY 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Alnylam Pharmaceuticals, Inc. (NasdaqNM:ALNY) Delayed quote dataEdit
Last Trade:16.93 USD
Trade Time: 8:00AM AEST
Change:Up 0.02 (0.12%)
Prev Close:16.91
Open:17.07
Bid:16.48 x 100
Ask:17.30 x 2000
1y Target Est:26.17
Day's Range:16.88 - 17.36
52wk Range:14.82 - 24.75
Volume:140,306
Avg Vol (3m):248,418
Market Cap:707.93M
P/E (ttm):N/A
EPS (ttm):-1.19
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add ALNY to Portfolio   Download Data

 HEADLINES 
Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics
Business Wire (Tue 12:00AM)
Alnylam to Webcast Presentation at The 12th Annual BIO CEO & Investor Conference
Business Wire (Tue, Feb 2)
Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21
Business Wire (Tue, Jan 26)
The Noble Gesture That Wasn't
at Motley Fool (Fri, Jan 22)
BIO Ventures for Global Health Chosen as Administrator of Intellectual Property Pool Involving GSK and Alnylam as Participants
Business Wire (Thu, Jan 21)
Alnylam and Collaborators Present Data from Multiple Pre-Clinical and Clinical Programs at RNAi Keystone Symposium
Business Wire (Wed, Jan 20)
Alnylam and Collaborators Discover Additional Class of Novel Lipid Nanoparticles with Markedly Improved In Vivo Potency for RNAi Therapeutics
Business Wire (Tue, Jan 19)
Alnylam's Kreutzer-Limmer I Patent Upheld in German Opposition Proceedings
Business Wire (Fri, Jan 15)
Regulus Therapeutics Present New Pre-clinical Data from Multiple Therapeutic Programs at Keystone Symposium
Business Wire (Fri, Jan 15)
Alnylam Pharma Guides
Zacks.com (Fri, Jan 15)
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Business Wire (Tue, Jan 12)
More Headlines for ALNY...

 ANALYST 
EPS Est (next year) (Dec-09) :-1.26
EPS Est (in 2 years) (Dec-10) :-1.44
Avg Rec (current)*:2.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics based on RNA interference (RNAi).

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices